Biotechnology Health Canada has approved the New Drug Submission (NDS-CV) for Moderna’s Spikevax (elasomeran mRNA vaccine), which has been known as COVID-19 Vaccine Moderna, for active immunization to prevent COVID-19 in individuals 12 years of age and older, with the news sending the US biotech’s shares up as much as 4% to $446.66 on Thursday. 17 September 2021